Noritate

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noritate

Quick Facts

Property Description
Active Ingredient Metronidazole
Form Cream (Topical Preparation)
Pharmacological Class Nitroimidazole Antibiotic, Antiprotozoal Agent
Origin Synthetic
Route of Administration Topical (External)

What is Noritate and What Class of Medicine Does It Belong To?

Noritate is a prescription-only medicine (POM) that uses the synthetic compound metronidazole as its single active ingredient. Metronidazole is a member of the imidazole class of anti-bacterial agents and is categorized as both an antiprotozoal and an antibacterial agent. This classification establishes the drug's core identity as a medication designed to target specific organisms and inflammatory processes within the skin.

This preparation is specifically known for its cream formulation, which distinguishes it from other topical metronidazole forms, such as gels or lotions. The use of the topical preparation ensures that the active substance is concentrated at the site of concern to assist in the management of localized skin inflammation. The medicine's fundamental characteristics support its specific function in managing persistent skin issues.

Noritate’s Composition and General Purpose

The product is supplied as an emollient cream, which acts as the vehicle for delivering the metronidazole to the skin. The final product is a single-ingredient drug, meaning its effect is derived solely from the action of metronidazole. The general purpose of this formulation is to help manage the visible, inflammatory signs of certain chronic skin conditions, such as reducing the erythema (redness) often seen in adult dermatological patients.

This benefit is rooted in metronidazole's anti-inflammatory properties, which help to calm swelling in the affected skin. Additionally, the antimicrobial activity targets organisms that may contribute to irritation and the development of inflammatory lesions. This focused therapeutic option acts by calming the underlying inflammation and reducing associated microbial activity.

What side effects are possible with Noritate?

Possible Side Effects and Safety Information

The officially documented safety profile for Noritate (metronidazole topical cream) centers on local reactions at the application site, while also noting the low-level potential for systemic effects from absorption. This structure aligns with regulatory classifications established by authorities such as the FDA and the EMA.

Adverse Reactions Classified by Frequency and System

Classification System-Organ Class Examples of Reactions
Common (1% to 10%) Skin and subcutaneous tissue disorders Skin irritation, pruritus (itching), erythema (redness), dryness, burning, and stinging.
Frequency Not Known Nervous System / Gastrointestinal Disorders Peripheral neuropathy, metallic taste, nausea, and dizziness, which are associated with systemic exposure.

Safety Considerations and Restrictions

While predominantly acting locally, official labeling includes several safety restrictions and special considerations:

  • Avoidance of Contact: Contact with the eyes and other mucous membranes must be strictly avoided to prevent local irritation and lacrimation (tearing).
  • Discontinuation Note: If severe or persistent local irritation occurs, regulatory documents state that the use of the product should be discontinued.
  • Systemic Exposure: Due to the possibility of systemic absorption, the potential for central nervous system effects and peripheral neuropathy (typically associated with oral metronidazole) should be considered.
  • Special Populations: Caution is advised when used in patients taking oral anticoagulants, as metronidazole may potentiate their effect. Use during pregnancy is documented as only appropriate if clearly needed.

Post-marketing reports also note rare instances of a Systemic Lupus Erythematosus (SLE) flare-up, a clinically significant adverse reaction documented in official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for metronidazole topical cream confirms that there are no reported human experiences with overdosage of the topical formulation, and this specific fact forms the initial basis of the drug's official overdose profile according to government authorities. This profile emphasizes that topically applied metronidazole can be absorbed through the skin in sufficient amounts to potentially produce systemic effects, which is the primary regulatory concern.

Documented Systemic Risk and Manifestations

Due to the potential for systemic exposure, the risk profile highlights the potential for serious neurological manifestations. Specifically, regulators document the risk of peripheral neuropathy, which is a systemic adverse reaction reported in post-marketing experience. The clinical signs associated with this outcome include the onset of tingling or numbness of the extremities (paresthesia).

When to Seek Urgent Help

When such abnormal neurologic signs appear, official regulatory documents mandate that the user seek immediate clinical reevaluation of the ongoing therapy. This requirement establishes a clear and mandatory trigger for seeking urgent medical attention, focusing on these specific, documented systemic manifestations of exposure. The regulatory guidance does not specify supportive measures or the existence of an antidote within the topical overdose section, nor does it include separate population-specific considerations for overdose.

Therapeutic Uses of Noritate

What Noritate Treats: Main Uses and Benefits

Targeting Inflammatory Lesions in Rosacea

Noritate (metronidazole cream) is principally used in dermatology for the localized management of rosacea. The medication is specifically applied in conditions involving symptoms related to inflammatory or irritative states, notably addressing papules (small, red bumps) and pustules (pus-filled lesions). This use contributes to easing the overall symptom load, which is relevant in clinical settings that involve acute or unstable symptom patterns. The primary symptoms the medication helps address include the inflammatory lesions of rosacea and persistent facial redness (erythema).


Support for Chronic Skin Management

Noritate is commonly used in situations involving conditions characterized by periods of heightened symptoms, specifically for the ongoing, long-term control of this recurrent skin disorder. The cream may assist with the symptomatic management of the persistent facial erythema often seen alongside the inflammatory outbreaks. This application contributes to a sense of stability when symptoms are more noticeable.

“This topical support contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.”


Quick Fact: Symptomatic Support for Rosacea

Noritate plays a role in managing the visible inflammatory manifestations of the disease, providing symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. FDA DailyMed label for Metronidazole Topical Cream

Eligibility and Restrictions for Use

Noritate (metronidazole topical cream) is officially regulated for use in specific populations, with clear restrictions based on age, hypersensitivity, and physiological status.

Contraindicated Populations

Use is contraindicated in patients with a known history of hypersensitivity (allergic reaction) to metronidazole or to any other ingredients within the cream formulation. This is an absolute prohibition stated in official labeling.


Age-Group and Restricted Use

The medicine is primarily indicated for use in adults.

  • Pediatric Patients: Safety and effectiveness have not been established in children or adolescents, and use is generally not recommended in those under 16 years of age.
  • Older Adults: The dosage for older adults is typically the same as that recommended for younger adults.

Conditional Use and Special Caution

Official documents mandate that Noritate be used with care in patients with a history of blood dyscrasia (blood disorders) and with caution in patients with a history of Central Nervous System (CNS) diseases.

For pregnant or nursing women, use is generally permitted only if clearly needed, and regulatory bodies advise considering discontinuing nursing if the drug is essential to the mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Noritate (metronidazole cream) addresses specific interaction risks established with the oral form of metronidazole, which must be considered due to the potential for low systemic absorption with topical use.

Documented Interaction Patterns

The regulatory profile identifies two main areas of concern based on pharmacologic action:

  • Oral Anticoagulants (Exposure-Modifying Interaction): Systemic metronidazole is reported to potentiate the anticoagulant effect of coumarin and related derivatives, such as warfarin. This interaction can lead to a prolongation of prothrombin time. While the effect of the topical cream on prothrombin time is not known, caution is required for patients concurrently receiving anticoagulant treatment [FDA DailyMed label].

  • Alcohol (Pharmacodynamic Interaction): Co-consumption of alcohol (ethanol) with metronidazole, even in topical form, carries a documented risk of a disulfiram-like reaction (e.g., flushing, tachycardia). This interaction is strictly prohibited during therapy and for at least 48 hours after the final dose, as stated in the product labeling [HPRA SmPC].

Interaction-Related Restrictions

Classification Restriction Type Requirement as per Label
Substance Restriction Alcohol Avoidance Strictly avoid alcohol during treatment and for 48 hours post-treatment
Patient Caution Anticoagulant Therapy Interaction must be kept in mind for patients on warfarin or coumarin derivatives

Mechanism of Action

Action on Cellular Oxidative Stress

The mechanism of metronidazole is defined by a highly localized, dual-action pharmacodynamic profile within the skin. The primary action involves chemically interfering with the cellular machinery of inflammatory cells. The drug functions as an inhibitor of Reactive Oxygen Species (ROS) generation within immune cells like neutrophils, which are central to local inflammatory processes. This molecular suppression of the oxidative burst reduces the highly reactive chemical output of the immune response, resulting in a reduction of the localized inflammatory response.

Action on Anaerobic Microbial Physiology

A secondary but complementary mechanistic domain involves the drug's established antimicrobial activity. Metronidazole requires intracellular reduction to become active, allowing it to specifically target and disrupt the DNA of susceptible anaerobic microorganisms and protozoa. This focused cytotoxic action reduces the local microbial load, which influences the inflammatory cycle.

Dosage and Administration Information

How to Use Noritate

Noritate (metronidazole 1% cream) is a prescription medicine formulated exclusively for topical use and is applied externally to the skin. The medication is not intended for ophthalmic, oral, or intravaginal administration.


Standard Application Protocol

The standard adult dosing regimen involves applying a thin film of the cream to the entire affected area once daily (q.d.). The amount to be applied is typically described as approximately a 1/2 cm ribbon of cream, which should be rubbed into the skin lightly.

Prior to application, the areas to be treated must be cleansed. Patients are permitted to use cosmetics after the cream has been absorbed or dried, which integrates the treatment into the daily routine.


Duration and Specific Use Constraints

Treatment is commonly initiated as a defined course, with controlled studies demonstrating continuous improvement through 8 to 10 weeks of therapy. Therapeutic results should become evident within the first month of consistent use. While the cream may be used as part of a long-term management plan, information regarding the dosage required for extended administration is characterized as uncertain.

A key administration constraint is the requirement to avoid contact with the eyes during application. The safety and effectiveness of the 1% cream have not been established for use in pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Noritate


Evidence for Inflammatory Lesions of Rosacea (Papules and Pustules)

The primary clinical research exploring Noritate (metronidazole cream) has been used in research exploring how symptoms change over time related to the inflammatory lesions (papules and pustules) of rosacea. This research mainly consists of short-term randomized controlled trials (RCTs). These studies typically involved adult participants diagnosed with moderate to severe papulopustular rosacea. In these controlled research settings, findings describe patterns observed in the studies regarding the presence of these skin lesions. Studies also examined the Investigator's Global Assessment (IGA) Score, a rating of overall disease severity.

However, research efforts exploring short-term symptom changes are common, but there is limited information for long-term outcomes. Additionally, the results apply only to the populations studied, and data for certain groups remain insufficient, particularly for those with the most complex or advanced rosacea presentations.


Evidence for Persistent Facial Redness (Erythema) of Rosacea

Research has also explored whether application of the cream was associated with outcomes linked to inflammatory or irritative states such as persistent facial redness, or erythema. These studies were generally conducted as part of the same short-term randomized controlled trials as the inflammatory lesion research. They examined how facial redness changes over the study period in the observed adult populations, primarily using standardized severity scales. Findings for erythema varied across studies regarding the extent of change reported, and the evidence base for redness alone is not as extensive as it is for the inflammatory lesions.

Understanding Research Gaps and Uncertainties

Research has been crucial in establishing what is currently known about Noritate, but evidence highlights what is known — and what is still uncertain. The main research primarily consists of short-term (12 weeks or less) studies, meaning long-term outcomes are not fully characterized and follow-up durations were limited for understanding long-term maintenance. The sample sizes were modest in some of the original registration trials, and evidence quality varies across studies when synthesizing the results across different formulations and research groups. Overall, research is ongoing to better characterize long-term outcomes and the impact on diverse patient populations.

Frequently Asked Questions (FAQ)

Common questions about Noritate (FAQ)


Q: What is the difference between Noritate and other topical metronidazole creams or gels, like MetroGel?

Studies have compared Noritate (metronidazole 1% cream) to other topical metronidazole formulations, including 1% gels. Findings indicate that changes in inflammatory lesions were generally comparable between the cream and gel formulations in controlled research settings. The key difference between these products is the formulation vehicle, such as whether the medicine is delivered in a cream, gel, or lotion.


Q: How long does it usually take to see an initial change when using Noritate?

Clinical research examining metronidazole topical formulations suggests that most of the overall effects may be observed within the first three weeks of use. Official documents also mention that therapeutic results are generally noted within the first month of consistent use in clinical settings.


Q: What is the expected full treatment duration for Noritate for rosacea symptoms?

The initial treatment course studied in controlled clinical trials for topical metronidazole formulations typically ranges from 7 to 12 weeks. The specific treatment duration is determined by a healthcare professional.


Q: Can Noritate be used long-term to keep rosacea symptoms from coming back (maintenance therapy)?

The cream is sometimes used as part of a long-term management plan for rosacea. However, official regulatory labeling notes that information regarding the dosage required for extended administration is considered uncertain.


Q: Can Noritate affect or interact with any alcohol-containing products that are applied to the skin?

Yes, official documents state that the use of metronidazole should be avoided with products containing alcohol (ethanol) or propylene glycol, even when applied to the skin. This restriction is noted in official documentation during therapy and for at least 48 hours after the final dose because of the potential for a systemic disulfiram-like reaction.


Q: Is there any data on using Noritate during pregnancy or while breastfeeding?

According to official labeling, there are no adequate and well-controlled studies of Noritate cream use in pregnant women. For nursing women, metronidazole is known to be secreted in human milk after oral administration. A choice between discontinuing nursing or discontinuing the drug is necessary, with the drug’s importance to the mother being considered.


Q: Can I apply makeup or sunscreen over the top of Noritate cream?

Official prescribing information indicates that cosmetics may be applied to the skin after the cream has been allowed time to absorb or dry.


Q: Do studies support the use of Noritate for all subtypes of rosacea?

Clinical studies for Noritate primarily evaluated adult patients with inflammatory lesions (papules and pustules) and erythema (redness). The research efforts did not include patients with all specific presentations of rosacea, such as rhinophyma or ocular involvement.


Q: What happens if someone accidentally gets Noritate in their eyes?

Contact with the eyes and other mucous membranes must be strictly avoided to prevent local irritation. If accidental contact does occur, the official guidance notes that the eyes should be rinsed right away with water.


Q: Does Noritate help reduce flushing or just fixed redness?

Clinical research efforts for Noritate primarily examine outcomes related to the reduction of persistent facial redness (erythema) using standardized severity scales. The studies do not specifically isolate or measure the drug’s effect on transient flushing episodes.


Q: Does Noritate help with the redness (erythema) of rosacea, or only the bumps and pimples?

Clinical research findings have described changes associated with Noritate cream for both the inflammatory lesions (papules and pustules) and persistent facial redness (erythema) over the course of treatment.


Q: Does using Noritate make the skin more sensitive to sunlight or UV light?

Some authoritative medical sources note the importance of avoiding or minimizing exposure of the treated areas to strong sunlight and other sources of UV light.


Q: Are there any non-prescription products that are known to interact with Noritate?

The official warnings about interactions focus on the consumption of alcohol and concurrent use of oral anticoagulants. Regulatory documents also note the need to avoid products containing alcohol or propylene glycol, which may be found in some non-prescription products.


Q: Are there any dietary interactions or foods that must be avoided while using Noritate?

The primary restriction mentioned in the official documents concerning consumption involves alcoholic beverages. Co-consumption must be strictly avoided during treatment and for at least 48 hours after the final dose.


Q: What happens if a person misses a dose of Noritate?

If a dose is missed, it should be applied as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Official guidance indicates that a double amount should not be applied to compensate for a missed dose.


Q: Can people with sensitive skin or other skin conditions use Noritate?

Official labeling notes that if a reaction suggesting local skin irritation—which may be a concern for those with sensitive skin—occurs, the product’s use should be discontinued.


Q: Is there any research that specifically compares the 1% concentration of Noritate to the 0.75% metronidazole formulations?

Clinical reviews examining different metronidazole formulations indicate that the reductions in inflammatory lesions observed were generally consistent across the 0.75% and 1% strengths when compared to a placebo.


Q: Does Noritate contain any common allergens like parabens or fragrances?

The inactive ingredients listed in the official DailyMed label for Noritate cream include the preservatives methylparaben and propylparaben. No fragrance is explicitly listed as a component of the cream.


Q: Is Noritate primarily intended to treat the cause of rosacea or just the symptoms?

Official documents indicate that the drug is used for the topical treatment of the inflammatory lesions of rosacea. While the exact mechanism of action in rosacea is described as unknown, it appears to include an anti-inflammatory effect that targets the symptoms.


Q: Is there a maximum recommended length of time a person can use Noritate?

Official guidance indicates that treatment cessation is appropriate if a clear clinical improvement is not evident after the first 3 to 4 months of use. The continued use of the medicine is determined by a healthcare professional.


Q: How does the cream vehicle of Noritate affect its use compared to a gel or lotion?

Studies that have compared the cream vehicle with gel preparations of metronidazole formulations have found no significant difference in the cumulative potential for skin irritation between the two types of vehicles.

How should Noritate be stored and disposed of?

Noritate (metronidazole cream) 1% must be stored according to specific regulatory conditions to maintain stability and effectiveness.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Handling The cream must be protected from freezing.
Child Safety Keep out of the reach of children at all times.

Disposal

For home use, disposal of unused or expired Noritate cream and its containers should be managed through the community's solid waste management system. Regulatory assessments indicate that disposal through standard channels is not expected to cause adverse environmental effects.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noritate found in:

A-Z Index: